+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05800275

Phase II Study of Tucatinib, Capecitabine, and Intrathecal Trastuzumab for HER2-Positive Breast Cancer Patients with Leptomeningeal Metastases

Led by UNICANCER · Updated on 2025-11-18

30

Participants Needed

11

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of tucatinib, capecitabine, and intrathecal trastuzumab in patients with HER2-positive metastatic breast cancer that has spread to the leptomeninges, the membranes covering the brain and spinal cord. This Phase II study aims to assess the overall survival rate at 12 months in patients requiring intrathecal therapy due to leptomeningeal progression. The trial is sponsored by UNICANCER and focuses on patients with confirmed leptomeningeal metastases from breast cancer. Participants receive weekly intrathecal trastuzumab injections at a dose of 150 mg, oral tucatinib tablets of 300 mg twice daily, and capecitabine tablets of 1000 mgm twice daily on days 1 to 14 of each 21-day cycle. This single-arm study follows patients during treatment to monitor their response and safety over time. During the study, participants will undergo regular evaluations including neurological symptom assessments, imaging to track disease progression, quality of life questionnaires, cognitive testing, and toxicity monitoring. These assessments occur frequently during the first 18 months and then less often up to 42 months. Researchers will measure outcomes such as overall survival, progression-free survival, response in cerebrospinal fluid, and duration of leptomeningeal metastases response. The study requires participants to adhere to scheduled visits, laboratory tests, and follow-up procedures throughout the trial period.

CONDITIONS

Brief Title

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Research Team

T

Telma ROQUE, PhD

J

Jérôme LEMONNIER, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here